Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 3,096 Shares

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 3,096 shares of the business’s stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $50.13, for a total value of $155,202.48. Following the sale, the director now owns 279,787 shares of the company’s stock, valued at approximately $14,025,722.31. This represents a 1.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Pro-Dex Trading Up 1.2 %

Shares of NASDAQ:PDEX opened at $49.98 on Friday. The company has a market capitalization of $162.98 million, a PE ratio of 24.87 and a beta of 0.68. Pro-Dex, Inc. has a 12-month low of $16.84 and a 12-month high of $59.60. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.33. The business’s fifty day simple moving average is $40.13 and its 200-day simple moving average is $39.75.

Pro-Dex (NASDAQ:PDEX) last announced its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. As a group, equities research analysts predict that Pro-Dex, Inc. will post 2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pro-Dex

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC raised its holdings in Pro-Dex by 34.9% during the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after purchasing an additional 1,028 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Pro-Dex by 9.1% during the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after buying an additional 2,296 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Pro-Dex by 2.2% in the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock valued at $740,000 after buying an additional 529 shares in the last quarter. Ritholtz Wealth Management acquired a new position in shares of Pro-Dex during the 4th quarter worth approximately $572,000. Finally, Bank of New York Mellon Corp purchased a new stake in Pro-Dex in the fourth quarter valued at approximately $202,000. 15.28% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut shares of Pro-Dex from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.